Immunosupressive

Question 0

Thronbovytopenia

Answer 0

Thrombopoetin and oprelvekin (IL11)

Question 1

Anemia (especially in renal failure)

Answer 1

EPO

Question 2

Recovery of bone marrow

Answer 2

Filgastrim sagramostim

Question 3

RCC metastatic melanoma

Answer 3

Aldesleukin (IL2)

Question 4

Multiple sclerosis

Answer 4

IFN B

Question 5

Chronic hepatitis B and a
Kaposi sarcoma
Hairy cell leukemia 
condylomata acuminatum 
Renal cell carcinoma
Malignant melanoma

Answer 5

IFN a

Question 6

CGD

Answer 6

IFN gamma

Question 7

CLL targeting CD52

Answer 7

aLYMTuzumab for chronic LYMphocytic leukemia

Question 8

Colorectal cancer
Renal cell carcinoma
Targeting VEGF

Answer 8

Bevacizumab

Question 9

Stage IV colorectal cancer
Head and neck cancer
Targeting EGFR

Answer 9

Cetuximab

Question 10

B cell NHL
RA with mtx
ITP
Targeting CD20

Answer 10

Rituximab

Question 11

Breast cancer and gastric cancer targeting HER2/neu

Answer 11

Trastuzumab

Question 12

IBD, RA, ankylosing spondylitis, psoriasis targeting TNF-a

Answer 12

Infliximab, adalimumab

Question 13

Multiple sclerosis, Crohn disease a4-integrin target

Answer 13

Natalizumab

Risk of PML in patients with JC Virus

Question 14

Anti-platelet agent for prevention of ischemic complications in patients undergoing percutaeneous coronary intervention targeting Glycoprotein IIb/IIIa

Answer 14

Abciximab

Question 15

Osteoporosis; inhibitis osteoclast maturation (mimics osteoprotegrin) targeting RANKL

Answer 15

Denosumab

Question 16

Antidote for digoxin toxicity

Answer 16

Digoxin immune Fab

Question 17

Allergic asthma; prevents IgE binding to FceRI

Answer 17

Omalizumab

Question 18

RSV prophylaxis for high-risk infants to target the RSV F protein

Answer 18

PaliVIzumab - VIrus

Question 19

Calcineurin inhibitor which binds to cyclophylin. Thus blocking T cell activation by preventing IL-2 transcription. Gingival hyperplasia and nephrotoxic.

Answer 19

Cyclosporine

Question 20

Calcineurin inhibitor which binds to FK506. Thus blocking T cell activation by preventing IL-2 transcription. No ginvival hyperplasia or hirsutism.

Answer 20

Tacrolimus

Question 21

mTOR inhibitor; bind FKBP. Blocks T cell activation and B cell differentiation by preventing IL-2 signal transdcution.

Answer 21

Kidney SIRvives. Synergystic with cyclosporine.

Sirolimus (Rapamycin)

Question 22

Monoclonal antibody; blocks IL2R

Answer 22

Basiliximab

Question 23

Antimetabolite precursor of 6-MP. Injinits lymphocyte proliferation by blocking nucleotide synthesis. For Transplant rejection, RA, Crohn disease, GN

Answer 23

Azathiprine

Question 24

Inhibit NF-kB. Suppress both B and T cell function by decreasing transcription of many cytokines

Answer 24

Glucocorticoids.